DE69634752T2 - Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element" - Google Patents
Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element" Download PDFInfo
- Publication number
- DE69634752T2 DE69634752T2 DE69634752T DE69634752T DE69634752T2 DE 69634752 T2 DE69634752 T2 DE 69634752T2 DE 69634752 T DE69634752 T DE 69634752T DE 69634752 T DE69634752 T DE 69634752T DE 69634752 T2 DE69634752 T2 DE 69634752T2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- psa
- prostate
- gene
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title claims description 77
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title claims description 71
- 239000013598 vector Substances 0.000 title claims description 37
- 108091027981 Response element Proteins 0.000 title claims description 20
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 104
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 7
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 7
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 191
- 108090000623 proteins and genes Proteins 0.000 claims description 115
- 239000003623 enhancer Substances 0.000 claims description 32
- 238000012217 deletion Methods 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 20
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 108700019146 Transgenes Proteins 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims description 2
- 230000001902 propagating effect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 abstract description 11
- 108091023040 Transcription factor Proteins 0.000 abstract description 9
- 102000040945 Transcription factor Human genes 0.000 abstract description 9
- 230000002103 transcriptional effect Effects 0.000 abstract description 8
- 230000001419 dependent effect Effects 0.000 abstract description 7
- 230000029812 viral genome replication Effects 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 92
- 241001135569 Human adenovirus 5 Species 0.000 description 87
- 239000013612 plasmid Substances 0.000 description 74
- 239000012634 fragment Substances 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 42
- 101150075174 E1B gene Proteins 0.000 description 34
- 238000003752 polymerase chain reaction Methods 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 29
- 239000013615 primer Substances 0.000 description 28
- 238000013518 transcription Methods 0.000 description 27
- 230000035897 transcription Effects 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 25
- 238000003780 insertion Methods 0.000 description 20
- 230000037431 insertion Effects 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 19
- 238000002744 homologous recombination Methods 0.000 description 15
- 230000006801 homologous recombination Effects 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 230000002238 attenuated effect Effects 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 9
- 229960004413 flucytosine Drugs 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000007547 defect Effects 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 210000005267 prostate cell Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 6
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 6
- 101710199711 Early E1A protein Proteins 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 6
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 6
- 239000003098 androgen Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 101150026402 DBP gene Proteins 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 230000000981 bystander Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101150066038 E4 gene Proteins 0.000 description 3
- 102100021736 Galectin-1 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000692 cap cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 2
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 2
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 2
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 2
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 2
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 2
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 2
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 2
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 2
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 2
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 2
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 2
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 2
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 2
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 2
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 2
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 2
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 2
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 2
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 2
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101150007425 L4 gene Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710134502 Mgp-operon protein 3 Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 101150106313 gbp gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US495034 | 1983-05-06 | ||
| US08/495,034 US5698443A (en) | 1995-06-27 | 1995-06-27 | Tissue specific viral vectors |
| PCT/US1996/010838 WO1997001358A1 (en) | 1995-06-27 | 1996-06-26 | Tissue specific viral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69634752D1 DE69634752D1 (de) | 2005-06-23 |
| DE69634752T2 true DE69634752T2 (de) | 2006-01-12 |
Family
ID=23966983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69634752T Expired - Fee Related DE69634752T2 (de) | 1995-06-27 | 1996-06-26 | Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element" |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5698443A (enExample) |
| EP (1) | EP0844888B1 (enExample) |
| JP (1) | JP4117347B2 (enExample) |
| AT (1) | ATE295739T1 (enExample) |
| AU (1) | AU729648B2 (enExample) |
| CA (1) | CA2222457A1 (enExample) |
| DE (1) | DE69634752T2 (enExample) |
| ES (1) | ES2242196T3 (enExample) |
| MX (1) | MX9800145A (enExample) |
| WO (1) | WO1997001358A1 (enExample) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US6676935B2 (en) * | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
| US7011976B1 (en) | 1997-03-03 | 2006-03-14 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US7001764B2 (en) * | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| US6254862B1 (en) | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US6110702A (en) * | 1996-03-27 | 2000-08-29 | The Regents Of The University Of California | PSA positive regulating (PSAR) sequences and uses thereof |
| AUPO023496A0 (en) * | 1996-05-31 | 1996-06-27 | Commonwealth Scientific And Industrial Research Organisation | Modified small RNA viruses |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| US5772993A (en) * | 1997-01-21 | 1998-06-30 | The University Of Virginia Patent Foundation | Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues |
| US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| US6100444A (en) * | 1997-02-11 | 2000-08-08 | University Of Rochester Medical Center | Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen |
| AU744725B2 (en) * | 1997-03-03 | 2002-02-28 | Cold Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| JP2002514075A (ja) * | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 |
| EP1905837A1 (en) * | 1997-03-03 | 2008-04-02 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| US6432700B1 (en) * | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| IL120485A0 (en) | 1997-03-19 | 1997-07-13 | Yeda Res & Dev | Modulators of the function of receptors of the TNF/NGF receptor family and other proteins |
| JP4812914B2 (ja) * | 1997-06-23 | 2011-11-09 | ユニバーシティ オブ サスカチュワン | ウシアデノウイルスタイプ３ゲノム |
| EP1002103B1 (en) | 1997-08-04 | 2007-10-17 | Cell Genesys, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| US20030045492A1 (en) * | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| JP2002512938A (ja) * | 1997-09-19 | 2002-05-08 | ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド | ヒトを対象としたトランスジェニック自家ｔ−細胞治療および関連する組成物およびキット |
| US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7470426B1 (en) * | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| WO1999043697A1 (en) * | 1998-02-25 | 1999-09-02 | The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno | Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms |
| JP2002520069A (ja) * | 1998-07-14 | 2002-07-09 | メルク・アンド・カンパニー・インコーポレーテッド | アデノウイルスに基づくプロモーターアッセイ |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| US20060024273A1 (en) * | 1998-12-30 | 2006-02-02 | Henderson Daniel R | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| AU4246900A (en) * | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US8063022B1 (en) | 1999-06-08 | 2011-11-22 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| US7267978B1 (en) | 1999-10-14 | 2007-09-11 | The Regents Of The University Of California | Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression |
| KR20080046750A (ko) * | 2000-03-24 | 2008-05-27 | 바이오스피어 메디칼 인코포레이티드 | 능동 색전화용 미소구 |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| DE60137208D1 (de) | 2000-03-24 | 2009-02-12 | Cell Genesys Inc | Menschliche zellspezifische urotheliale regulatorische sequenzen der transkription des uroplakins, dessen vektoren und verwendungsverfahren |
| US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
| US7048920B2 (en) * | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| EP1283722A1 (en) * | 2000-03-31 | 2003-02-19 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| US20040101825A1 (en) * | 2001-09-26 | 2004-05-27 | Van Meir Erwin G. | Viruses targeted to hypoxic cells and tissues |
| US7285414B2 (en) * | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
| EP1207205A1 (en) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Adenoviral replicons |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| AU2002229679B2 (en) * | 2000-12-28 | 2007-12-20 | Per Sonne Holm | Use of transcription factor YB-1 in adenoviral systems |
| EP1425413A2 (en) * | 2001-01-23 | 2004-06-09 | Irm, Llc | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| WO2002068627A2 (en) * | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
| JP2004536607A (ja) * | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| US20030099616A1 (en) * | 2001-07-25 | 2003-05-29 | Irving John M. | Dual specificity tumor killing vectors driven by the telomerase promoter |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| ES2335657T3 (es) * | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| US7364727B2 (en) * | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050095705A1 (en) * | 2003-04-15 | 2005-05-05 | Michael Kadan | Method for production of oncolytic adenoviruses |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US20050079158A1 (en) * | 2003-06-05 | 2005-04-14 | Shenzhen Allucks Biotech Co., Ltd. | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof |
| DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
| WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| US20050271622A1 (en) * | 2004-06-03 | 2005-12-08 | Shenzhen Allucks Biotech Co., Ltd. | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof |
| GB0416487D0 (en) * | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
| US20090221477A1 (en) * | 2004-07-26 | 2009-09-03 | Asterion Limited | Linkers |
| US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| CA2598806A1 (en) | 2005-02-23 | 2006-08-31 | Uab Research Foundation | Alkyl-glycoside enhanced vaccination |
| US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| MX2007013914A (es) | 2005-05-09 | 2008-02-22 | Biosphere Medical S A | Composiciones y metodos que usan microesferas y agentes de contraste no ionicos. |
| DK2118292T3 (da) | 2007-01-30 | 2011-10-24 | Transgene Sa | Papillomavirus E2-polypeptid der anvendes til vaccination |
| SG196837A1 (en) | 2009-01-20 | 2014-02-13 | Transgene Sa | Soluble icam-1 as biomarker for prediction of therapeutic response |
| EP2408904B1 (en) | 2009-03-20 | 2017-10-18 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
| DK2411815T3 (en) | 2009-03-24 | 2015-11-30 | Transgene Sa | Biomarker MONITORING OF PATIENTS |
| DK2419728T3 (da) | 2009-04-17 | 2014-02-03 | Transgene Sa | Biomarkør til at overvåge patienter |
| RU2552292C2 (ru) | 2009-07-10 | 2015-06-10 | Трансжене Са | Биомаркер для отбора пациентов и связанные с ним способы |
| GB0919773D0 (en) | 2009-11-12 | 2009-12-30 | Univ Nottingham | Induced pluripotent stem cell |
| CN101899420A (zh) * | 2010-01-16 | 2010-12-01 | 韩从辉 | 一种靶向抗前列腺肿瘤的表达超抗原基因的双调控溶瘤腺病毒的制备方法 |
| US20130210663A1 (en) | 2010-08-04 | 2013-08-15 | Cizzle Biotechnology Limited | Methods and compounds for the diagnosis and treatment of cancer |
| GB201016852D0 (en) | 2010-10-07 | 2010-11-17 | Univ York | Cell differentiation |
| GB201102091D0 (en) | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
| GB201102090D0 (en) | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
| EP2912069B1 (en) | 2012-10-23 | 2019-07-31 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| WO2019056015A2 (en) | 2017-09-18 | 2019-03-21 | Children's Hospital Medical Center | STRONG ISOLATOR AND ITS USES IN GENE ADMINISTRATION |
| US12168042B2 (en) | 2019-06-28 | 2024-12-17 | Massachusetts Institute Of Technology | Circular strained zymogen compositions and methods of use |
| CN115315273A (zh) | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | Il-2直向同源物及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9001828A (nl) * | 1990-08-15 | 1992-03-02 | Centraal Diergeneeskundig Inst | Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde. |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| JP3875990B2 (ja) * | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| KR100285171B1 (ko) * | 1994-09-30 | 2001-03-15 | 모리시타 요이찌 | 테이프 접착장치 및 방법 |
| US5919652A (en) * | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
| FI972225A7 (fi) * | 1994-11-28 | 1997-07-16 | Genetic Therapy Inc | Vektorit kudosspesifistä replikaatiota varten |
| CA2206205A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors |
| US20030026789A1 (en) * | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| AU5750196A (en) * | 1995-05-18 | 1996-11-29 | Genetic Therapy, Inc. | Gene therapy of hepatocellular carcinoma through cancer-specific gene expression |
-
1995
- 1995-06-27 US US08/495,034 patent/US5698443A/en not_active Expired - Fee Related
-
1996
- 1996-06-26 DE DE69634752T patent/DE69634752T2/de not_active Expired - Fee Related
- 1996-06-26 ES ES96923418T patent/ES2242196T3/es not_active Expired - Lifetime
- 1996-06-26 AU AU63932/96A patent/AU729648B2/en not_active Ceased
- 1996-06-26 EP EP96923418A patent/EP0844888B1/en not_active Expired - Lifetime
- 1996-06-26 CA CA002222457A patent/CA2222457A1/en not_active Abandoned
- 1996-06-26 AT AT96923418T patent/ATE295739T1/de not_active IP Right Cessation
- 1996-06-26 JP JP50451797A patent/JP4117347B2/ja not_active Expired - Fee Related
- 1996-06-26 US US08/669,753 patent/US5871726A/en not_active Expired - Fee Related
- 1996-06-26 WO PCT/US1996/010838 patent/WO1997001358A1/en not_active Ceased
-
1998
- 1998-01-07 MX MX9800145A patent/MX9800145A/es not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4117347B2 (ja) | 2008-07-16 |
| WO1997001358A1 (en) | 1997-01-16 |
| JPH11508770A (ja) | 1999-08-03 |
| MX9800145A (es) | 1998-11-30 |
| DE69634752D1 (de) | 2005-06-23 |
| US5871726A (en) | 1999-02-16 |
| EP0844888A4 (en) | 1999-11-03 |
| AU729648B2 (en) | 2001-02-08 |
| ATE295739T1 (de) | 2005-06-15 |
| EP0844888B1 (en) | 2005-05-18 |
| ES2242196T3 (es) | 2005-11-01 |
| US5698443A (en) | 1997-12-16 |
| EP0844888A1 (en) | 1998-06-03 |
| AU6393296A (en) | 1997-01-30 |
| CA2222457A1 (en) | 1997-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69634752T2 (de) | Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element" | |
| DE69534791T2 (de) | Vektoren zur gewebsspezifischen replikation | |
| DE69838584T2 (de) | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung | |
| DE69936663T2 (de) | Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung | |
| DE69839071T2 (de) | Adenovirale vektoren spezifisch für zellen, welche alpha-fetoprotein exprimieren, sowie methoden zu deren verwendung | |
| DE60035124T2 (de) | Ein oncolytisches adenovirus | |
| DE69834936T2 (de) | Vektor zur gewebespezifischen replikation und expression | |
| DE69914382T2 (de) | Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression | |
| DE69425989T3 (de) | Neue Komplementations-Zelllinien für defekte adenovirale Vektoren | |
| DE69637432T2 (de) | Adenovirale vektoren für die gentherapie | |
| DE69534878T2 (de) | Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren | |
| DE60014489T3 (de) | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten | |
| DE69633565T2 (de) | Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie | |
| EP2403951B1 (en) | Tumor-selective adenovirus e1a and e1b mutants | |
| US20030044383A1 (en) | Tissue specific adenoviral vectors | |
| WO1996014061A9 (en) | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods | |
| JP2003265193A (ja) | 組換えｐ５３アデノウイルス | |
| JPH09509330A (ja) | 分子間相同組換えによるウイルスベクターの作製方法 | |
| JPH10505484A (ja) | 相補的なアデノウイルスベクター系と細胞系 | |
| EP1268761B1 (en) | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof | |
| DE69828167T2 (de) | Rekombinante adenovirale vektoren, die eine spleissequenz enthalten | |
| AU2001245944A1 (en) | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof | |
| DE60027364T2 (de) | Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer | |
| US20020025307A1 (en) | Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues | |
| US20020068049A1 (en) | Tissue specific adenoviral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |